Clene Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Clene Inc. (CLNN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $5.51 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- Clene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $5.36, a 26.12% increase year-over-year.
- Clene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $4.25, a 865.91% increase year-over-year.
- Clene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.44, a 66.15% decline year-over-year.
- Clene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.30, a 57.10% decline year-over-year.
- Clene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $5.09, a 26.23% decline from fiscal 2024.
- Clene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $6.90, a 650.00% increase from fiscal 2023.
- Clene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $0.92, a 53.06% decline from fiscal 2022.
- Clene Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.96, a 74.01% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.51 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $5.36 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $5.09 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $4.81 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $3.93 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $4.25 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | $6.90 10-K · filed 2025-03-24 | |||
| 2024-09-30 | $7.04 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $7.44 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $0.44 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $0.92 10-K · filed 2024-03-13 | |||
| 2023-09-30 | $0.95 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $0.97 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $1.30 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | $1.96 10-K · filed 2023-03-13 | |||
| 2022-09-30 | $3.01 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $3.01 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $3.03 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $7.54 10-K · filed 2022-03-11 | |||
| 2021-09-30 | $8.85 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $8.87 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $6.55 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $5.48 10-K · filed 2021-03-29 | |||
| 2019-12-31 | $2.42 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |